Work

Safety and tolerability of FOLFIRABRAX [5-Fluourouracil (5-FU), irinotecan (IRI), and nab-paclitaxel (NP)] with genotype-guided dosing of IRI in previously untreated advanced gastrointestinal (GI) cancer patients (pts): A multicenter trial of the University of Chicago Personalized Cancer Care Consortium.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.e16241

Authors: Smita Suhas Joshi, Theodore Karrison, Daniel V.T. Catenacci, Jaclyn D Peterson, Mark Zalupski, Brooke Elizabeth Phillips, Ahad Ali Sadiq, Amikar Sehdev, James Lloyd Wade, Vincent J. Picozzi, Andrea Louise Amico, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Hedy L. Kindler, Manish Sharma

Institutions: University of Chicago, University of Chicago Medical Center, University of Michigan, Indiana University Indianapolis, Heartland Cancer Research, Virginia Mason Medical Center, Endeavor Health, Ingalls Memorial Hospital

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891024671

Cites:

Cited by:

Related to: 10